Search

Your search keyword '"Ziranu A"' showing total 74 results
Start Over Author "Ziranu A" Publisher elsevier bv
74 results on '"Ziranu A"'

1. Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial

Author

Debora Basile, Gerardo Rosati, Francesca Bergamo, Silvio Ken Garattini, Maria Banzi, Maria Zampino, Silvia Bozzarelli, Paolo Marchetti, Fabio Galli, Francesca Galli, Raffaella Longarini, Alberto Zaniboni, Daris Ferrari, Sabino De Placido, Luca Giovanni Frassineti, Mario Nicolini, Saverio Cinieri, Michele Priscindiaro, Pina Ziranu, Riccardo Caccialanza, Alessandro Pastorino, Stefania Mosconi, and Giuseppe Aprile

Subjects
Oncology, Gastroenterology
Published
2023

2. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment

Author

Andrea Pretta, Pina Ziranu, Riccardo Giampieri, Clelia Donisi, Erika Cimbro, Dario Spanu, Eleonora Lai, Federica Pecci, Francesca Balconi, Alessio Lupi, Marta Pozzari, Mara Persano, Sara Murgia, Valeria Pusceddu, Marco Puzzoni, Rossana Berardi, and Mario Scartozzi

Subjects
Hepatology, Gastroenterology
Abstract

Association between pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (DM2) has long been evaluated. Indeed, DM2 can be both an epiphenomenon of PDAC and a risk factor. The present study aimed to investigate the correlation between overall survival (OS) and antidiabetic drugs in patients with metastatic pancreatic ductal adenocarcinoma and DM2.Data from 232 patients were collected retrospectively from 2014 to 2021. 174 from AOU Cagliari Medical Oncology and 58 from AOU Ancona Medical Oncology. All patients received gemcitabine plus nab-paclitaxel first-line chemotherapy. We aimed to evaluate the correlation between DM2, anti-diabetic medications and overall survival. Survival distribution was assessed by Kaplan-Meier curves.Median age was 68±9, 127 (55%) were male. 138/232 (59%) patients were not affected by DM2, 94/232 (41%) were affected by DM2. 57 were insulin-treated and 37 were metformin-treated. DM2 treated patients showed an higher median overall survival (26 vs 12 months, p = 0,0002). Among DM2 patients insulin-treated and metformin-treated showed an mOS of 21 months and 33 months, respectively.Results showed a correlation between treated DM2 and higher mOS in patients with mPDAC. Limitations due to retrospective data collection must be considered. Further studies in this setting are needed.

Published
2023

3. Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score

Author

Ziranu, Pina, primary, Ferrari, Paolo Albino, additional, Guerrera, Francesco, additional, Bertoglio, Pietro, additional, Tamburrini, Alessandro, additional, Pretta, Andrea, additional, Lyberis, Paraskevas, additional, Grimaldi, Giulia, additional, Lai, Eleonora, additional, Santoru, Massimiliano, additional, Bardanzellu, Fabio, additional, Riva, Laura, additional, Balconi, Francesca, additional, Della Beffa, Eleonora, additional, Dubois, Marco, additional, Pinna-Susnik, Matteo, additional, Donisi, Clelia, additional, Capozzi, Enrico, additional, Pusceddu, Valeria, additional, Murenu, Alessandro, additional, Puzzoni, Marco, additional, Mathieu, Federico, additional, Sarais, Sabrina, additional, Alzetani, Aiman, additional, Luzzi, Luca, additional, Solli, Piergiorgio, additional, Paladini, Piero, additional, Ruffini, Enrico, additional, Cherchi, Roberto, additional, and Scartozzi, Mario, additional

Published
2023
Full Text
View/download PDF

4. Prognostic value of Body Mass Index in stage II/III colon cancer: post-hoc analysis from the TOSCA trial

Author

Basile, D., primary, Rosati, G., additional, Bergamo, F., additional, Garattini, S.K., additional, Banzi, M., additional, Zampino, M., additional, Bozzarelli, S., additional, Marchetti, P., additional, Galli, F., additional, Longarini, R., additional, Zaniboni, A., additional, Ferrari, D., additional, De Placido, S., additional, Frassineti, L., additional, Nicolini, M., additional, Cinieri, S., additional, Priscindiaro, M., additional, Ziranu, P., additional, Caccialanza, R., additional, Pastorino, A., additional, Mosconi, S., additional, and Aprile, G., additional

Published
2023
Full Text
View/download PDF

5. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, M., primary, Giommoni, E., additional, Bergamo, F., additional, Milella, M., additional, Cavanna, L., additional, Di Marco, M.C., additional, Spada, M., additional, Cordio, S., additional, Aprile, G., additional, Cardellino, G.G., additional, Maiello, E., additional, Bernardini, I., additional, Ghidini, M., additional, Bozzarelli, S., additional, Macchini, M., additional, Orsi, G., additional, De Simone, I., additional, Rulli, Er., additional, Porcu, L., additional, Torri, V., additional, Pinto, C., additional, Reni, Michele, additional, Macchini, Marina, additional, Orsi, Giulia, additional, Peretti, Umberto, additional, Valente, Mariamaddalena, additional, Giommoni, Elisa, additional, Antonuzzo, Lorenzo, additional, Di Costanzo, Francesco, additional, Bergamo, Francesca, additional, Zagonel, Vittorina, additional, Lonardi, Sara, additional, Buggin, Federica, additional, Milella, Michele, additional, Palmerio, Silvia, additional, Cavanna, Luigi, additional, Di Nunzio, Camilla, additional, Di Marco, Maria Cristina, additional, Grassi, Elisa, additional, Spada, Massimiliano, additional, Messina, Marco, additional, Cordio, Stefano, additional, Avola, Francesco, additional, Aprile, Giuseppe, additional, Pagano, Salvatore, additional, Simionato, Francesca, additional, Cardellino, Giovanni Gerardo, additional, Majer, Federica, additional, Maiello, Evaristo, additional, Latiano, Tiziana Pia, additional, Chiarazzo, Cinzia, additional, Artioli, Fabrizio, additional, Razzini, Giorgia, additional, Pasqualini, Antonella, additional, Ghidini, Michele, additional, Binda, Elisa, additional, Lazzarelli, Silvia, additional, Bozzarelli, Silvia, additional, Sala, Simona, additional, Luppi, Gabriele, additional, Pettorelli, Elisa, additional, Spallanzani, Andrea, additional, Vicario, Giovanni, additional, Salmaso, Flavia, additional, Basso, Marco, additional, Silvestris, Nicola, additional, Del Curatolo, Sabina, additional, Zustovich, Fable, additional, Bongiovanni, Francesca, additional, Longobardi, Ciro, additional, Sandi, Ilenia, additional, Fontanella, Caterina, additional, Montelatici, Silvia, additional, Giordano, Monica, additional, Luchena, Giovanna, additional, Gilardoni, Micol, additional, Tamburini, Emiliano, additional, Rudnas, Britt, additional, Venturini, Barbara, additional, Merelli, Barbara, additional, Negrini, Giorgia, additional, Vici, Elio Maria, additional, Marabese, Alessandra, additional, Garetto, Cristina, additional, Curcio, Paola, additional, Cinieri, Saverio, additional, Cinefra, Margherita, additional, Ferrara, Pasqualinda, additional, Cantore, Maurizio, additional, Morselli, Patrizia, additional, Fumi, Guglielmo, additional, Isidori, Agnese, additional, Ciccarese, Giovanni, additional, Paolo Frassineti, Giovanni Luca, additional, Pagan, Flavia, additional, Vaccaro, Vanja, additional, Spoto, Chiara, additional, Ferrara, Marianna, additional, Garufi, Carlo, additional, Caporale, Marta, additional, Vasile, Enrico, additional, Salani, Francesca, additional, Barone, Elisa, additional, Berardi, Rossana, additional, Onofri, Azzurra, additional, Ballatore, Zelmira, additional, Lucarelli, Alessandra, additional, Barucca, Alessandra, additional, Pancotti, Amedeo, additional, Scipioni, Teresa, additional, Bencardino, Katia, additional, Marrapese, Giovanna, additional, Idotta, Laura, additional, Petrelli, Fausto, additional, Lonati, Veronica, additional, Ceribelli, Anna, additional, Giuli, Angelo, additional, Zannori, Cristina, additional, Bassanelli, Maria, additional, Mambrini, Andrea, additional, Ginocchi, Laura, additional, Orlandi, Massimo, additional, Celio, Luigi, additional, Niger, Monica, additional, Biamonte, Lavinia, additional, Tamberi, Stefano, additional, Piancastelli, Alessandra, additional, Papiani, Giorgio, additional, Valli, Irene, additional, Allione, Paolo, additional, Boe, Maria Giovanna, additional, Scartozzi, Mario, additional, Lai, Eleonora, additional, Pireddu, Annagrazia, additional, Ziranu, Pina, additional, Demurtas, Laura, additional, Puzzoni, Marco, additional, Mariani, Stefano, additional, Pretta, Andrea, additional, Liscia, Nicole, additional, Savastano, Clementina, additional, Malaspina, Valentina, additional, Tonini, Giuseppe, additional, Grassani, Teresa, additional, Barco, Barbara, additional, Pierosandro, Tagliaferri, additional, Ciliberto, Domenico, additional, Ierardi, Antonella, additional, Calandruccio, Natale Daniele, additional, Minotti, Vincenzo, additional, Matocci, Roberta, additional, Torri, Valter, additional, Porcu, Luca, additional, Rulli, Erica, additional, De Simone, Irene, additional, Carlucci, Luciano, additional, Rulli, Eliana, additional, Poli, Davide, additional, Tonto, Paola, additional, Scellato, Francesca, additional, and Pinto, Carmine, additional

Published
2023
Full Text
View/download PDF

6. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment

Author

Pretta, Andrea, primary, Ziranu, Pina, additional, Giampieri, Riccardo, additional, Donisi, Clelia, additional, Cimbro, Erika, additional, Spanu, Dario, additional, Lai, Eleonora, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Persano, Mara, additional, Murgia, Sara, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

7. 118P Immunosenescence and response to immunotherapy in elderly patients: A possible prognostic tool

Author

Pretta, A., primary, Donisi, C., additional, Ziranu, P., additional, Liscia, N., additional, Loi, F., additional, Saba, G., additional, Pretta, G., additional, Spanu, D., additional, Dubois, M., additional, Atzori, F., additional, Pusceddu, V., additional, Puzzoni, M., additional, Massa, E., additional, Madeddu, C., additional, Lai, E., additional, Astara, G., additional, and Scartozzi, M., additional

Published
2022
Full Text
View/download PDF

8. The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials

Author

Dubois, Marco, primary, Liscia, Nicole, additional, Brunetti, Oronzo, additional, Ziranu, Pina, additional, Lai, Eleonora, additional, Argentiero, Antonella, additional, Mazza, Elena, additional, Cascinu, Stefano, additional, Silvestris, Nicola, additional, Casadei-Gardini, Andrea, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

10. Fibrin sealant reduces need for transfusions after hip hemiarthroplasty for femoral neck fractures

Author

A Ziranu, Maria Serena Oliva, Nicola Piccirillo, Elisa Pesare, Michele Cauteruccio, Giuseppe Sircana, and Felice Minutillo

Subjects
Fibrin sealant, medicine.medical_specialty, Proximal femur fractures, Arthroplasty, Replacement, Hip, Blood volume, Fibrin Tissue Adhesive, Femoral Neck Fractures, Fibrin, 03 medical and health sciences, 0302 clinical medicine, Belgium, medicine, Humans, Blood Transfusion, General Environmental Science, Femoral neck, 030222 orthopedics, Subcapital fractures, biology, Femoral neck fractures, business.industry, Sealant, Blood loss, Transfusion rate, Soft tissue, 030208 emergency & critical care medicine, Perioperative, Hip hemiarthroplasty, Settore MED/33 - MALATTIE APPARATO LOCOMOTORE, Surgery, Treatment Outcome, medicine.anatomical_structure, biology.protein, General Earth and Planetary Sciences, Hemiarthroplasty, Implant, business
Abstract

Introduction Every year more than 300,000 proximal femur fractures are diagnosed. Their number will double within 30 years. In femoral neck fractures treated with hip hemiarthroplasty 90-days mortality is 29.5-51.6%. Haemorrhage is one amongst other complications that is associated with increasing postoperative mortality. Transfusion rate in these patients ranges from 25.7% to 39%. Blood transfusions expose to complications. Fibrin sealants are useful in reducing perioperative need for transfusions, total blood loss, blood loss from drainage. The aim of this study is to assess whether the use of a fibrin sealant during hip hemiarthroplasty implant reduces the need for transfusion. Patient and methods All patients admitted with a proximal femur fracture from September 2018 to May 2019 were reviewed. Inclusion criteria were: femoral neck fracture AO 31B2-3, hip hemiarthroplasty. Exclusion criteria were: previous surgery on the affected hip, coagulation disorders, hematopoietic disorders. Patients were divided in fibrin sealant group and control group. All patients underwent partial hip replacement through a posterolateral approach. 4 ml of fibrin sealant (EVICEL, Omrix Biopharmaceuticals, Diegem, Belgium) were sprayed on the soft tissues of patients included in the fibrin sealant group. Primary outcome of our study was need for perioperative transfusion. Secondary outcomes were: mean red blood cell transfused volume, variations in haematocrit and haemoglobin and total blood volume loss. Results Eighty-one consecutive patients were enrolled. EVICEL was used on 19 patients, standard haemostatic care on 62 patients. Two patients were transfused in the fibrin sealant group, 22 in the control group (p 0,0371). Mean transfused volume was 21,05 ml in the fibrin sealant group and 116,16 ml in the control group (p 0,0017). No significant difference could be found in haematocrit and haemoglobin variation and total blood loss. Discussion A reduction in transfusional need with the use of fibrin sealants was reported in studies on total hip arthroplasty and was confirmed by our study. Conclusion EVICEL reduces need for transfusion in patients undergoing hip hemiarthroplasty for a femoral neck fracture. It must be held among the options when a stricter control on transfusional requirement is needed.

Published
2020

11. The use of knee mega-prosthesis for the management of distal femoral fractures: A systematic review

Author

A Ziranu, Giulio Maccauro, F Minutillo, Maria Concetta Meluzio, MF Saccomanno, and Oliva

Subjects
medicine.medical_specialty, Activities of daily living, Megaprothesis, medicine.medical_treatment, Aseptic loosening, Periprosthetic, Knee replacement, Prosthesis, Distal femoral fractures, Knee fractures, Non oncological fractures, law.invention, Intramedullary rod, Fracture Fixation, Internal, 03 medical and health sciences, 0302 clinical medicine, Quality of life, law, Activities of Daily Living, medicine, Humans, Stage (cooking), Aged, Retrospective Studies, General Environmental Science, 030222 orthopedics, business.industry, 030208 emergency & critical care medicine, Settore MED/33 - MALATTIE APPARATO LOCOMOTORE, Surgery, Treatment Outcome, Quality of Life, General Earth and Planetary Sciences, Periprosthetic Fractures, Knee Prosthesis, business, Femoral Fractures
Abstract

Introduction Distal femur fractures (DFFs) are unusual and difficult to deal, especially in elderly patients. A consensus about a gold-standard treatment has not been reached yet. Available options include both conservative and surgical management. In elderly patients a prosthetic replacement could be a valid treatment option. Literature is lacking about the use of mega-prosthesis in this type of fractures. The purpose of the present systematic review is to examine which fracture, both acute and chronic, involving distal femur should be treated by using a mega-prosthesis. Materials and Methods Studies were identified by searching electronic databases. All studies that enrolled people of any age affected by a DFFs treated by using a megaprosthesis were included. Primary outcomes of the present reviews were: ROM, functional assessment and complications. Two review authors independently selected eligible trials. Disagreements at any stage were resolved by consensus or a third party adjudication. Descriptive statics was used to summarize the data. Results Thirteen article were finally included in the review. One hundred-four patients were treated with knee megaprosthesis. Three categories of patients were identified: 29 patients were affected by supracondylar femur fracture; 51 patients occurred with a periprosthetic fracture; 24 patients suffered a non-union of a previous supracondylar fracture. The follow-up varied between 6 months to 58 months. All studies showed good results in terms of improving quality of life, resuming activities of daily living (ADLs), early mobilization, ROM, shorter hospital stay. Although not frequent, the only reported complications were infection and aseptic loosening. Discussion The present review showed that the use of knee megaprosthetic implants could represent a valid treatment option aiming to reduce patients’ immobilitazion and hospital stay. Good clinical outcomes with low rate of complications were reported by all included studies. Literature is lacking about long-term outcomes and complications. Moreover studies comparing knee prostheses and other types of surgical treatment (intramedullary nails, plate fixation system) are needed. Conclusions Megaprosthesis represent a viable treatment option in patients affected by DFFs (either acute, periprostethic or non-union) because they allow immediate weight-bearing, shorter hospital stay, a fast recovery of knee function and ADLs.

Published
2020

12. Euthyroid sick syndrome in hip fractures: Evaluation of postoperative anemia

Author

Michele Cauteruccio, Sircana G, Piccirillo N, Carlo Perisano, A Ziranu, Giulio Maccauro, Raffaele Vitiello, Marcello Covino, and Elisa Pesare

Subjects
Pediatrics, medicine.medical_specialty, Acute coronary syndrome, Anemia, transfusion rate, femoral neck fractures, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Postoperative Period, blood loss, Aged, General Environmental Science, Aged, 80 and over, Nonthiyroidal Illness Syndrome, 030222 orthopedics, Hip fracture, Hip Fractures, business.industry, Mortality rate, Incidence (epidemiology), 030208 emergency & critical care medicine, medicine.disease, Euthyroid Sick Syndromes, Settore MED/33 - MALATTIE APPARATO LOCOMOTORE, Thyroxine, proximal femur fractures, Concomitant, Euthyroid Sick Syndrome, General Earth and Planetary Sciences, Thyroid function, business, Euthyroid sick syndrome
Abstract

Introduction Incidence of hip fractures is increasing with upward estimates representing one of the most current health problems. According to some authors this condition is associated with an early mortality rate ranging between 20% and 35% and low outcomes. One of the predictive factors of poor outcome after hip fracture is anaemia. In fragile patients, hormonal changes due to fracture and surgical trauma, may occur in the hypophyseal hypothalamus axis which may lead to the Euthyroid Sick Syndrome (ESS). This pathological condition is characterized by a reduction in the concentration of triiodothyronine (T3) with normal or slightly reduced thyrotropin (TSH) values and with or without a reduction (cancellata) ​​of thyroxine (T4). ESS has been associated to an increased mortality in elderly patients. Materials and methods Inclusion criteria were: age > 65y, X-ray diagnosis of proximal femoral fracture classified as AO 31A or 31B requiring surgical treatment, admittance to the emergency room within 72 hours from trauma. Exclusion criteria were: any thyroid-related pathology, concomitant acute coronary syndrome, active pneumonia, concomitant neoplastic disease, assumption of medications able to affect thyroid function, refusal to undergo surgical treatment. All patients underwent routine blood testing and a complete thyroid-hormone profile dosage before surgical operation. The same blood tests performed before surgical operation were repeated on the first and third post-operative days. Results Thirtytwo patients met the inclusion criteria and were enrolled after they accepted to participate to the study. Sixteen patients presented with ESS on admission and 16 patients did not. The mean age was 82,5 yo. There was no statistically significant difference in bleeding risk factors among the two groups. In the ESS group there was a number of blood transfusions of 1.06 units higher than the control group (p=0.01). Conclusions We have demonstrated that patients with ESS have a higher need of red blood cells transfusion compared to patients without ESS and, thus they have a higher risk to develop anemia in the peri-operative period. We believe it would be useful to diagnose ESS in fragile patients at their arrival to the emergency room and apply a peri-operative therapeutic protocol to prevent anemia.

Published
2020

15. 490P New horizons in metastatic colorectal cancer: Role of CD44 expression

Author

Ziranu, P., primary, Aimola, V., additional, Pretta, A., additional, Cerrone, G., additional, Persano, M., additional, Liscia, N., additional, Dubois, M., additional, Migliari, M., additional, Sarais, F., additional, Cimbro, E., additional, Parrino, A., additional, Spanu, D., additional, Mariani, S., additional, Donisi, C., additional, Pinna, G., additional, Pusceddu, V., additional, Puzzoni, M., additional, Lai, E., additional, Faa, G., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

16. 467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial

Author

Lai, E., primary, Murgioni, S., additional, Ziranu, P., additional, Basile, D., additional, Cherri, S., additional, Madeddu, C., additional, Bergamo, F., additional, Piacentini, G., additional, Smiroldo, V., additional, Squadroni, M., additional, De Grandis, M.C., additional, Mascia, L., additional, Rosati, G., additional, Zampino, M.G., additional, Spallanzani, A., additional, Conca, V., additional, Palladino, M.A., additional, Flaminio, V., additional, Di Bella, S., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

17. 407P Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer

Author

Pretta, A., primary, Donisi, C., additional, Persano, M., additional, Pinna, G., additional, Cimbro, E., additional, Parrino, A., additional, Aimola, V., additional, Spanu, D., additional, Cerrone, G., additional, Deidda, S., additional, Deidda, M.A., additional, Pusceddu, V., additional, Puzzoni, M., additional, Ziranu, P., additional, Barbara, R., additional, Restivo, A., additional, Zorcolo, L., additional, Faa, G., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

18. 417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer

Author

Puzzoni, M., primary, Giampieri, R., additional, Mariani, S., additional, Ziranu, P., additional, Pusceddu, V., additional, Donisi, C., additional, Persano, M., additional, Pinna, G., additional, Cimbro, E., additional, Parrino, A., additional, Pretta, A., additional, Lai, E., additional, Liscia, N., additional, Lupi, A., additional, Giglio, E., additional, Palomba, G., additional, Casula, M., additional, Pisano, M., additional, Palmieri, G., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

19. 459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial

Author

Lai, E., primary, Lonardi, S., additional, Ziranu, P., additional, Cappetta, A., additional, Cherri, S., additional, Madeddu, C., additional, Murgioni, S., additional, Mosconi, S., additional, Smiroldo, V., additional, Squadroni, M., additional, Barsotti, G., additional, Mascia, L., additional, Rosati, G., additional, Zampino, M.G., additional, Gelsomino, F., additional, Conca, V., additional, Palladino, M.A., additional, Morelli, C., additional, Bollina, R., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

20. P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus

Author

Pretta, A., primary, Pinna, G., additional, Donisi, C., additional, Persano, M., additional, Cimbro, E., additional, Parrino, A., additional, Migliari, M., additional, Dubois, M., additional, Liscia, N., additional, Mariani, S., additional, Lai, E., additional, Pusceddu, V., additional, Puzzoni, M., additional, Ziranu, P., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

21. PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab

Author

Giampieri, R., primary, Lupi, A., additional, Ziranu, P., additional, Pecci, F., additional, Pretta, A., additional, Persano, M., additional, Crocetti, S., additional, Giglio, E., additional, Bittoni, A., additional, Mandolesi, A., additional, Scartozzi, M., additional, and Berardi, R., additional

Published
2021
Full Text
View/download PDF

22. P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy

Author

Pretta, A., primary, Donisi, C., additional, Persano, M., additional, Pinna, G., additional, Cimbro, E., additional, Parrino, A., additional, Migliari, M., additional, Dubois, M., additional, Liscia, N., additional, Mariani, S., additional, Lai, E., additional, Puzzoni, M., additional, Pusceddu, V., additional, Ziranu, P., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

23. P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients

Author

Pretta, A., primary, Persano, M., additional, Pinna, G., additional, Donisi, C., additional, Cimbro, E., additional, Parrino, A., additional, Migliari, M., additional, Dubois, M., additional, Mariani, S., additional, Liscia, N., additional, Lai, E., additional, Pusceddu, V., additional, Puzzoni, M., additional, Ziranu, P., additional, and Scartozzi, M., additional

Published
2021
Full Text
View/download PDF

24. Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study

Author

Lai, Eleonora, primary, Puzzoni, Marco, additional, Ziranu, Pina, additional, Cremolini, Chiara, additional, Lonardi, Sara, additional, Banzi, Maria, additional, Mariani, Stefano, additional, Liscia, Nicole, additional, Cinieri, Saverio, additional, Dettori, Manuela, additional, Mencoboni, Manlio, additional, Nappo, Floriana, additional, Piacentini, Giulia, additional, Labianca, Roberto, additional, Zucchelli, Gemma, additional, Boccaccino, Alessandra, additional, Conca, Veronica, additional, Pusceddu, Valeria, additional, Zaniboni, Alberto, additional, and Scartozzi, Mario, additional

Published
2021
Full Text
View/download PDF

25. 417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer

Author

Stefano Mariani, Milena Casula, Mara Persano, Alessio Lupi, Grazia Palomba, Nicole Liscia, Marco Puzzoni, Clelia Donisi, G. Pinna, E. Cimbro, Giovannella Palmieri, Andrea Pretta, A. Parrino, Marina Pisano, Riccardo Giampieri, Eleonora Lai, Valeria Pusceddu, Enrica Giglio, M. Scartozzi, and Pina Ziranu

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Internal medicine, medicine, Hematology, Liquid biopsy, medicine.disease, business
Published
2021

26. 407P Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer

Author

Mario Scartozzi, Andrea Pretta, Pina Ziranu, Mara Persano, Angelo Restivo, Marco Puzzoni, A. Parrino, Dario Spanu, Luigi Zorcolo, S. Deidda, Gavino Faa, M.A. Deidda, E. Cimbro, R. Barbara, Clelia Donisi, G. Pinna, G. Cerrone, Valeria Pusceddu, and V. Aimola

Subjects
Oncology, medicine.medical_specialty, Chemo-radiotherapy, business.industry, Colorectal cancer, Locally advanced, Hematology, medicine.disease, Internal medicine, medicine, DNA mismatch repair, In patient, business
Published
2021

27. 490P New horizons in metastatic colorectal cancer: Role of CD44 expression

Author

Eleonora Lai, Nicole Liscia, F. Sarais, Pina Ziranu, Clelia Donisi, G. Pinna, A. Parrino, Valeria Pusceddu, Marco Puzzoni, G. Cerrone, Dario Spanu, V. Aimola, Marco Dubois, Marco Migliari, Mara Persano, Stefano Mariani, Gavino Faa, E. Cimbro, Andrea Pretta, and Mario Scartozzi

Subjects
New horizons, Oncology, Expression (architecture), biology, Colorectal cancer, business.industry, CD44, medicine, Cancer research, biology.protein, Hematology, medicine.disease, business
Published
2021

28. P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients

Author

Mario Scartozzi, Pina Ziranu, E. Cimbro, Marco Puzzoni, Eleonora Lai, Mara Persano, A. Parrino, Marco Dubois, Marco Migliari, Valeria Pusceddu, Nicole Liscia, Clelia Donisi, G. Pinna, Andrea Pretta, and Stefano Mariani

Subjects
Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, Concomitant, Internal medicine, Overall survival, Medicine, Hematology, Progression-free survival, business, medicine.disease
Published
2021

29. Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study

Author

Pina Ziranu, Francesca Bergamo, Alessandra Anna Prete, Fabiana Pani, Sara Lonardi, Stefano Mariotti, Marco Puzzoni, Giuseppe Pasqualetti, Laura Rumano, Sabina Murgioni, Marta Schirripa, Giulia Alberti, Mario Scartozzi, Riccardo Giampieri, Fotios Loupakis, Mario Domenico Rizzato, Fabio Monzani, Silvia Stragliotto, Valeria Pusceddu, and Vittorina Zagonel

Subjects
Male, 0301 basic medicine, Oncology, Multivariate statistics, Survival, Pyridines, Colorectal cancer, Thyroid Function Tests, chemistry.chemical_compound, 0302 clinical medicine, Prospective Studies, Aged, 80 and over, Hazard ratio, Thyroid, Gastroenterology, Middle Aged, Prognosis, Progression-Free Survival, Deiodination, medicine.anatomical_structure, Italy, 030220 oncology & carcinogenesis, Cohort, Triiodothyronine, Female, Colorectal Neoplasms, FT(3)/FT(4), hormones, hormone substitutes, and hormone antagonists, Adult, medicine.medical_specialty, Refractory, Antineoplastic Agents, 03 medical and health sciences, Internal medicine, Regorafenib, medicine, Humans, Response Evaluation Criteria in Solid Tumors, Aged, business.industry, Phenylurea Compounds, medicine.disease, Survival Analysis, Confidence interval, Thyroxine, 030104 developmental biology, chemistry, business, Follow-Up Studies
Abstract

Background The impact of free triiodothyronine (FT3)/free thyroxine (FT4) ratio on survival in hospitalized geriatric patients was recently described. Up today, there are no data regarding the prognostic role of FT3/FT4 ratio in patients with advanced cancer. We evaluated the impact of FT3/FT4 ratio on survival in patients with refractory colorectal cancer (CRC) treated with regorafenib. Methods Patients with metastatic CRC treated with regorafenib with available clinical data and baseline measurement of FT3, FT4, and thyroid-stimulating hormone (TSH) were considered eligible. Exploratory analyses included subjects treated at Istituto Oncologico Veneto. A confirmatory analysis was planned based on FT3/FT4 ratio tertile results, and a validation cohort was built on data retrieved from University of Cagliari. Results In an exploratory cohort, the median overall survival in patients with low, intermediate, and high FT3/FT4 ratios, according to tertiles' value, was 4.8, 5.0, and 7.6 months, respectively (P = .003). The differences were significant in the multivariate model (hazard ratio, 0.43; 95% confidence interval, 0.28-0.68; P = .0003). Confirmatory results were obtained in a validation cohort, both in univariate (P = .0002) and in multivariate (hazard ratio, 0.56; 95% confidence interval, 0.36-0.88; P = .0118) models. Conclusions High baseline FT3/FT4 ratio is strongly associated to better outcome in patients with progressive metastatic CRC treated with regorafenib. Further investigations are ongoing to draw definitive conclusions regarding a potential predictive effect.

Published
2018

30. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?

Author

Lai, Eleonora, primary, Astara, Giorgio, additional, Ziranu, Pina, additional, Pretta, Andrea, additional, Migliari, Marco, additional, Dubois, Marco, additional, Donisi, Clelia, additional, Mariani, Stefano, additional, Liscia, Nicole, additional, Impera, Valentino, additional, Persano, Mara, additional, Tolu, Simona, additional, Balconi, Francesca, additional, Pinna, Giovanna, additional, Spanu, Dario, additional, Pireddu, Annagrazia, additional, Saba, Giorgio, additional, Camera, Silvia, additional, Musio, Francesca, additional, Puzzoni, Marco, additional, Pusceddu, Valeria, additional, Madeddu, Clelia, additional, Casadei Gardini, Andrea, additional, and Scartozzi, Mario, additional

Published
2021
Full Text
View/download PDF

31. 459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial

Author

Sabina Murgioni, Pina Ziranu, S. Cherri, Mario Scartozzi, Valeria Smiroldo, G. Rosati, A. Cappetta, M.G. Zampino, Fabio Gelsomino, Clelia Madeddu, S. Lonardi, Cristina Morelli, L. Mascia, M.A. Palladino, Eleonora Lai, Veronica Conca, M. Squadroni, R. Bollina, Stefania Mosconi, and G. Barsotti

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, FOLFIRI, Hematology, business, Interim analysis, Aflibercept, medicine.drug
Published
2021

32. 467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial

Author

S. Cherri, M. Squadroni, V. Flaminio, Pina Ziranu, Andrea Spallanzani, M.A. Palladino, Sabina Murgioni, Clelia Madeddu, L. Mascia, G. Rosati, M.C. De Grandis, Eleonora Lai, G. Piacentini, Debora Basile, Valeria Smiroldo, S. Di Bella, M.G. Zampino, Veronica Conca, Mario Scartozzi, and Francesca Bergamo

Subjects
Oncology, medicine.medical_specialty, business.industry, Monocyte, Subgroup analysis, Hematology, medicine.anatomical_structure, Internal medicine, FOLFIRI, Medicine, business, Aflibercept, medicine.drug
Published
2021

36. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial

Author

Pasqualetti, Giuseppe, primary, Schirripa, Marta, additional, Dochy, Emmanuelle, additional, Fassan, Matteo, additional, Ziranu, Pina, additional, Puzzoni, Marco, additional, Scartozzi, Mario, additional, Alberti, Giulia, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Monzani, Fabio, additional, and Loupakis, Fotios, additional

Published
2020
Full Text
View/download PDF

37. New therapeutic targets in pancreatic cancer

Author

Lai, Eleonora, primary, Puzzoni, Marco, additional, Ziranu, Pina, additional, Pretta, Andrea, additional, Impera, Valentino, additional, Mariani, Stefano, additional, Liscia, Nicole, additional, Soro, Paolo, additional, Musio, Francesca, additional, Persano, Mara, additional, Donisi, Clelia, additional, Tolu, Simona, additional, Balconi, Francesca, additional, Pireddu, Annagrazia, additional, Demurtas, Laura, additional, Pusceddu, Valeria, additional, Camera, Silvia, additional, Sclafani, Francesco, additional, and Scartozzi, Mario, additional

Published
2019
Full Text
View/download PDF

38. Corrigendum to “Gastric cancer: Translating novels concepts into clinical practice” [Cancer Treatm. Rev. 79C (2019) 101889]

Author

Salati, Massimiliano, primary, Orsi, Giulia, additional, Smyth, Elisabeth, additional, Aprile, Giuseppe, additional, Beretta, Giordano, additional, De Vita, Fernando, additional, Di Bartolomeo, Maria, additional, Fanotto, Valentina, additional, Lonardi, Sara, additional, Morano, Federica, additional, Pietrantonio, Filippo, additional, Pinto, Carmine, additional, Rimassa, Lorenza, additional, Vasile, Enrico, additional, Vivaldi, Caterina, additional, Zaniboni, Alberto, additional, Ziranu, Pina, additional, and Cascinu, Stefano, additional

Published
2019
Full Text
View/download PDF

39. PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab

Author

Federica Pecci, Mara Persano, Pina Ziranu, Alessandra Mandolesi, Enrica Giglio, Alessio Lupi, Andrea Pretta, Riccardo Giampieri, Alessandro Bittoni, R. Berardi, Sonia Crocetti, and Mario Scartozzi

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, Internal medicine, medicine, Hematology, First line chemotherapy, business, medicine.disease, medicine.drug
Published
2021

40. P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus

Author

Andrea Pretta, A. Parrino, Marco Dubois, Mario Scartozzi, Marco Migliari, Pina Ziranu, Eleonora Lai, Nicole Liscia, E. Cimbro, Clelia Donisi, G. Pinna, Marco Puzzoni, Mara Persano, Stefano Mariani, and Valeria Pusceddu

Subjects
medicine.medical_specialty, Pancreatic ductal adenocarcinoma, Oncology, business.industry, Internal medicine, medicine, Type 2 Diabetes Mellitus, Hematology, business, Gastroenterology
Published
2021

41. P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy

Author

A. Parrino, Andrea Pretta, Pina Ziranu, Mario Scartozzi, Marco Puzzoni, E. Cimbro, Mara Persano, Eleonora Lai, Stefano Mariani, Nicole Liscia, Clelia Donisi, G. Pinna, Marco Dubois, Valeria Pusceddu, and Marco Migliari

Subjects
Chemotherapy, Prognostic factor, Pancreatic ductal adenocarcinoma, business.industry, medicine.medical_treatment, Monocyte, Lymphocyte, Hematology, Gemcitabine, Therapy naive, medicine.anatomical_structure, Oncology, medicine, Cancer research, Stage iv, business, medicine.drug
Published
2021

42. Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab

Author

Lai, E., primary, Schirripa, M., additional, Puzzoni, M., additional, Loupakis, F., additional, Ziranu, P., additional, Pretta, A., additional, Giampieri, R., additional, Mariani, S., additional, Liscia, N., additional, Soro, P., additional, Pusceddu, V., additional, Astara, G., additional, Impera, V., additional, Camera, S., additional, Musio, F., additional, Zaniboni, A., additional, Fassan, M., additional, Lonardi, S., additional, Zagonel, V., additional, and Scartozzi, M., additional

Published
2019
Full Text
View/download PDF

43. Gastric cancer: Translating novels concepts into clinical practice

Author

Salati, Massimiliano, primary, Orsi, Giulia, additional, Smyth, Elisabeth, additional, Beretta, Giordano, additional, De Vita, Fernando, additional, Di Bartolomeo, Maria, additional, Fanotto, Valentina, additional, Lonardi, Sara, additional, Morano, Federica, additional, Pietrantonio, Filippo, additional, Pinto, Carmine, additional, Rimassa, Lorenza, additional, Vasile, Enrico, additional, Vivaldi, Caterina, additional, Zaniboni, Alberto, additional, Ziranu, Pina, additional, and Cascinu, Stefano, additional

Published
2019
Full Text
View/download PDF

44. A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Author

Loupakis, Fotios, primary, Intini, Rossana, additional, Cremolini, Chiara, additional, Orlandi, Armando, additional, Sartore-Bianchi, Andrea, additional, Pietrantonio, Filippo, additional, Pella, Nicoletta, additional, Spallanzani, Andrea, additional, Dell’Aquila, Emanuela, additional, Scartozzi, Mario, additional, De Luca, Emmanuele, additional, Rimassa, Lorenza, additional, Formica, Vincenzo, additional, Leone, Francesco, additional, Calvetti, Lorenzo, additional, Aprile, Giuseppe, additional, Antonuzzo, Lorenzo, additional, Urbano, Federica, additional, Prenen, Hans, additional, Negri, Francesca, additional, Di Donato, Samantha, additional, Buonandi, Pasquale, additional, Tomasello, Gianluca, additional, Avallone, Antonio, additional, Zustovich, Fable, additional, Moretto, Roberto, additional, Antoniotti, Carlotta, additional, Salvatore, Lisa, additional, Calegari, Maria Alessandra, additional, Siena, Salvatore, additional, Morano, Federica, additional, Ongaro, Elena, additional, Cascinu, Stefano, additional, Santini, Daniele, additional, Ziranu, Pina, additional, Schirripa, Marta, additional, Buggin, Federica, additional, Prete, Alessandra Anna, additional, Depetris, Ilaria, additional, Biason, Paola, additional, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Fassan, Matteo, additional, and Di Maio, Massimo, additional

Published
2019
Full Text
View/download PDF

45. Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine

Author

Mariani, S., primary, Soro, P., additional, Liscia, N., additional, Balconi, F., additional, Camera, S., additional, Donisi, C., additional, Impera, V., additional, Musio, F., additional, Persano, M., additional, Pireddu, A., additional, Pretta, A., additional, Tolu, S., additional, Pusceddu, V., additional, Lai, E., additional, Faloppi, L., additional, Demurtas, L., additional, Ziranu, P., additional, Puzzoni, M., additional, and Scartozzi, M., additional

Published
2019
Full Text
View/download PDF

46. A new prognostic score for biliary tract cancer: a multicenter experience

Author

Ziranu, P., primary, Lai, E., additional, Casadei Gardini, A., additional, Pretta, A., additional, Faloppi, L., additional, Andrikou, K., additional, Astara, G., additional, Orsi, G., additional, Impera, V., additional, Mariani, S., additional, Liscia, N., additional, Soro, P., additional, Musio, F., additional, Camera, S., additional, Tolu, S., additional, Madeddu, C., additional, Massa, E., additional, Pusceddu, V., additional, Demurtas, L., additional, Puzzoni, M., additional, Cascinu, S., additional, and Scartozzi, M., additional

Published
2019
Full Text
View/download PDF

47. Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience

Author

Pretta, A., primary, Lai, E., additional, Liscia, N., additional, Impera, V., additional, Camera, S., additional, Musio, F., additional, Mariani, S., additional, Soro, P., additional, Persano, M., additional, Donisi, C., additional, Tolu, S., additional, Balconi, F., additional, Atzori, F., additional, Dessì, M., additional, Massa, E., additional, Madeddu, C., additional, Pusceddu, V., additional, Astara, G., additional, Demurtas, L., additional, Puzzoni, M., additional, Ziranu, P., additional, and Scartozzi, M., additional

Published
2019
Full Text
View/download PDF

48. P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab

Author

Gianluca Masi, Carlotta Antoniotti, Nicole Liscia, Stefano Cascinu, Alfredo Falcone, A. Zaniboni, Luca Faloppi, Laura Casula, Mario Scartozzi, Cristian Loretelli, C. Cremolini, Fausto Meriggi, Marco Puzzoni, Fabio Gelsomino, Laura Demurtas, Riccardo Giampieri, Eleonora Lai, Valeria Pusceddu, Stefano Mariani, Alessandra Mandolesi, Pina Ziranu, and A. Cubeddu

Subjects
Oncology, medicine.medical_specialty, Cetuximab, Colorectal cancer, business.industry, Wild type, Hematology, Abnormal expression, medicine.disease, Irinotecan, Internal medicine, medicine, Line (text file), business, medicine.drug
Published
2018

49. Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab

Author

Giorgio Astara, Andrea Pretta, Francesca Musio, Valentino Impera, A. Zaniboni, Pina Ziranu, Vittorina Zagonel, Riccardo Giampieri, Mario Scartozzi, Valeria Pusceddu, Nicole Liscia, P. Soro, Marco Puzzoni, S. Lonardi, Fotios Loupakis, Marta Schirripa, Eleonora Lai, Matteo Fassan, Stefano Mariani, and S. Camera

Subjects
Oncology, medicine.medical_specialty, Cetuximab, Colorectal cancer, business.industry, Hematology, medicine.disease, digestive system diseases, Log-rank test, Irinotecan, Internal medicine, Cohort, medicine, Immunohistochemistry, Prospective cohort study, business, neoplasms, Survival analysis, medicine.drug
Abstract

Background Preclinical and clinical data support that p53 might modulate the EGFR activity and as a consequence it might influence response/resistance to anti-EGFR monoclonal antibodies. However, the association between p53 status and clinical outcome has not been clarified yet. In our study we evaluated the role of p53 expression in RAS/BRAF wild type (WT) metastatic colorectal (mCRC) patients (pts) receiving irinotecan-cetuximab by using a validation cohort. Methods p53 immunohistochemical expression was retrospectively analysed in tumour samples of RAS/BRAF WT mCRC pts treated with second-third line irinotecan-cetuximab. Our aim was to evaluate the correlation between p53 expression and OS, PFS and RR. Statistical analysis was performed with the MedCalc package. Survival distribution was assessed by the Kaplan-Meyer method and comparison of survival curves was performed with log-rank test. Results Globally 120 RAS/BRAF WT mCRC pts were included in our analysis, 88 in the exploratory cohort and 32 in the validation cohort. 36/88 and 14/32 pts had p53 normal expression, whereas 52/88 and 18/32 showed p53 overexpression. In the exploratory cohort, RR was 61.1% in pts with p53 normal expression versus (vs) 3.8% in pts overexpressing p53 (p Conclusions In our study p53 normal expression was associated with better outcome in RAS/BRAF WT mCRC pts receiving irinotecan-cetuximab, as confirmed by the validation cohort. Further prospective studies are needed to validate the role of p53 in these pts and to investigate its cross-talk with EGFR. Legal entity responsible for the study Mario Scartozzi. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Published
2019

50. Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience

Author

Eleonora Lai, Nicole Liscia, P. Soro, Clelia Donisi, Impera, S. Tolu, Pina Ziranu, Mara Persano, Laura Demurtas, Clelia Madeddu, Francesca Balconi, Francesco Atzori, Stefano Mariani, S. Camera, Francesca Musio, Marco Puzzoni, Pusceddu, Mario Scartozzi, Mariele Dessì, Elena Massa, Giorgio Astara, and Andrea Pretta

Subjects
Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, Hematology, medicine.disease, Single Center, Internal medicine, Concomitant, medicine, Overall survival, Progression-free survival, business
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results